SAB Biotherapeutics (NASDAQ:SABS) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of SAB Biotherapeutics (NASDAQ:SABS) from a sell rating to a strong sell rating in a report released on Sunday morning.

Several other research firms have also recently weighed in on SABS. Leerink Partners lifted their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, June 15th. Rodman & Renshaw restated a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Barclays started coverage on SAB Biotherapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.57 on Friday. The stock has a market capitalization of $272.96 million, a P/E ratio of -1.69 and a beta of 0.53. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $3.67 and a two-hundred day simple moving average of $3.83. SAB Biotherapeutics has a twelve month low of $1.85 and a twelve month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, research analysts anticipate that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. purchased a new position in shares of SAB Biotherapeutics in the first quarter worth $29,000. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics during the third quarter valued at $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter valued at $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter worth about $40,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.